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Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia.
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Introduction
Spi-1/PU.1 transgenic mice develop an acute erythroleukemia evolving as a two-step process 1 . The first step (HS1 stage) is characterized by a large hepatosplenomegaly associated to a severe anemia. Spleen and liver are infiltrated by preleukemic proerythroblasts arrested in maturation that remain strictly dependent upon erythropoietin (Epo) for proliferation and survival in vivo as well as in vitro. Spi-1/PU.1 is an ETS transcription factor that plays a critical role in regulating the commitment of multipotent hematopoietic progenitors and the development of the B lymphoid and monocytic lineages [2] [3] [4] [5] . The pathology that occurs in Spi-1/PU.1 transgenic mice thus indicates that overexpression of Spi-1/PU.1 in erythroid precursor cells impedes their maturation. However, later on during the disease progression, proerythroblastic cells emerge that are characterized by Epo autonomous growth and tumorigenicity in vivo. These proerythroblastic cells (HS2 stage) harbor gain-of-function mutations in the Kit gene encoding the tyrosine kinase receptor for SCF 6 . These mutations target the Kit kinase domain and confer a ligand-independent tyrosine kinase activity to the Kit receptor. Kit mutants cause growth factor-independent proliferation of proerythroblasts, thereby resulting in neoplastic transformation. Thus, the Spi-1/PU.1 model of erythroleukemic transformation involves the collaboration of at least 2 main events, one blocking differentiation and one inducing proliferation.
To further investigate the oncogenic events associated with this leukemic transformation process, we performed a proteomic profiling analysis to identify proteins differentially expressed in cells during the preleukemic (HS1) and the leukemic (HS2) stage. We found that ezrin was highly expressed in HS2 cells as compared to HS1 cells and we focused our study on this protein. Ezrin is a member of the Ezrin-Radixin-Moesin (ERM) protein family 7 .
Initially described as a cytoskeleton organizer in epithelial cells, ezrin participates to substrate adhesion, cell survival, cell motility and formation of cell-cell junctions 8, 9 . The NH2-terminal only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From 4 region anchors ezrin in the plasma membrane, whereas the COOH-terminal domain interacts with the actin cytoskeleton. In inactive state, the actin and membrane-binding domains are masked through intramolecular and/or intermolecular self-associations 9 . The functional activation of ezrin disrupts the closed conformation through a sequential process involving phosphatidyl(4,5)-bisphosphate (PIP 2 ) interaction, plasma membrane localisation and tyrosine/threonine phosphorylations [10] [11] [12] [13] . Notably, extracellular signals such as those mediated by the hepatocyte growth factor (HGF), the epidermal growth factor (EGF) or the plateletderived growth factor (PDGF) induce phosphorylation of ezrin in epithelial cells through stimulation of their transmembrane receptors [14] [15] [16] . Alternatively, ezrin can be activated by intracellular signaling factors such as the Src kinase Lck in T lymphocytes 17 or the Src 18 and
Rho pathway 10 in epithelial cells. Moreover, ezrin interacts with p85, the regulatory subunit of PI3-kinase and activates the PI3K/AKT pathway 16 .Thus, ezrin participates in signaling programs leading to its pleiotropic functions.
Several studies provide evidence that ezrin has a metastasis-promoting function in cancer.
Increased ezrin expression has been associated with high metastatic potential in a variety of human and rodent cancers, including pancreatic adenocarcinomas, osteosarcomas, rhabdomyosarcomas and breast carcinomas [19] [20] [21] [22] [23] [24] [25] . In the present study, we report that a dysregulation of ezrin is related to the progression of preleukemic proerythroblasts towards malignancy. We show that disruption of ezrin function by the ezrin mutants Y145F and Y335F leads to reduced proliferation and increased death of leukemic cells. Notably, we
show that ezrin is a downstream signaling effector of the oncogenic forms of Kit expressed in the leukemic proerythroblasts. Together, our data suggest that ezrin might be an important element in the oncogenic processes associated to activating mutations in tyrosine kinases.
only.
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Materials and Methods
Cell lines, growth kinetics and colony assays
HS1 and HS2 spi-1-transgenic cell lines have been previously described 1, 6 . For growth kinetics, cells were plated at 2 × 10 5 cells/mL. PP1 and PP2 (Calbiochem, La Jolla, CA), LY294002 (PI3 kinase inhibitor, Sigma), and Imatinib mesilate (Novartis-Pharma, Basel, Switzerland) were added at the indicated concentrations in culture medium. Living cells in culture were separated from dead cells through ficoll (Histopaque-1077, Sigma-Aldrich Chemie Gmbh, Germany) gradient centrifugation (30 min, 400g).
Clonogenic assays were performed in 1% methylcellulose medium (MethoCult M3134, Stem cell Technologies, Tebu, France) supplemented with 1% FBS and Epo (1U/mL). Fourhundred growing cells were seeded into 1.5mL medium in 30-mm dishes and colonies (50 cells at least) were counted on day 6 of incubation.
DNA constructs and transfections
The human VSVG-tagged ezrin constructs (WT, Nter, Y145F and Y335F) were cloned into the pEF-neo vector by standard cloning procedures. pEF-BOS-Kit D814Y and pEF-BOS-Kit WT were described previously 6 . pMKIT-Flt3 D835Y was supplied by Dr. P. Dubreuil (Inserm, Marseille, France) 26 and pcDNA3-myc-TEL-Jak2 was described previously 27 . Two micrograms of plasmids were transfected in COS-7 cells with Lipofectamine-PLUS reagent according to manufacturer instructions (Invitrogen, Cergy, France). Spi-1-transgenic proerythroblasts were nucleofected with 5µg of plasmids using an Amaxa nucleofector (Biosystems) and G16 program. Transfectants were selected in growth medium containing 800 µg/mL G418 (Invitrogen, Cergy, France).
Determination of apoptotic cells by Hoechst staining
Cells were fixed with PBS containing 4% paraformaldehyde for 10 min at room temperature, washed in PBS, and stained for 10 min with 50mg/mL Hoechst 33342 (Molecular Probes, 
Western blotting and antibodies
The following primary antibodies were used : the monoclonal anti-VSVG (VSVG P5D4 clone) (Roche Diagnostics, Mississauga, Ontario, Canada), a polyclonal antibody directed against the carboxy-terminal domain of ezrin 28 , a rabbit anti-TEL immune serum 27 , a rabbit immune anti-Kit serum 26 , the anti-phosphotyrosine 4G10 clone (Upstate Biotechnology, Lake BrdU removal prior to fixing. Immunodetection of incorporated BrdU, estimation of phases S, G2/M and potential doubling time (Tpot) calculations were achieved as described 30 .
Flow cytometry analyses were performed using FACScalibur (Beckton Dickinson, Meylan, France). Data were analyzed with FlowJo (Treestar, San Carlos, CA) software for Akt labeling and BrdU and ModFitLT (Verity, Topsham, ME) software for G1/S/G2 determination.
Tumorigenicity
Cells (1x10 7 in 0.5mL α-MEM medium containing 2% FBS) were injected subcutaneously into 8 week-old female nude mice. Tumor nodules were taken off after 3 weeks and weighted.
Results
Ezrin expression is increased in leukemic HS2 spi-1-transgenic proerythroblasts
To assess changes in protein expression that could play a role during the leukemic progression of spi-1-transgenic proerythroblasts, we performed a comparative proteomic profiling between preleukemic HS1 and leukemic HS2 cells. Protein extracts were resolved by bidirectional gel electrophoresis (shown in Supplementary Data 1). The differentiallydetected protein spots were subjected to trypsin digestion and the resulting peptides were analyzed by MALDI-TOF mass spectrometry. We focused our study on ezrin whose expression was higher in HS2 than in HS1 extracts. This observation was further confirmed by Western blot analysis of extracts prepared from independent HS1 and HS2 cell lines.
Indeed, ezrin expression was 3 to 5-fold increased in extracts from HS2 cells compared with extracts from HS1 cells, except for the 622HS2 cell line (Fig.1A) . Notably, among the HS2 cell lines, cell line 622 was previously characterized as autocrine for Epo shown by the presence of fragmented nuclei detected by Hoechst staining (Fig.2D) .
Accordingly, the mature active form (17kDa) of caspase-3 processed during apoptosis 31 was detected in extracts from 606HS2-Ez Nter cells on Western blotting (Fig.2E ).
The VSVG-Ezrin Nter expression construct was also stably-transfected into 663HS1 cells. The
Epo-dependent proliferation rates and the viability of 663HS1-Ez Nter and 663HS1-Ez WT cells only.
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Altogether, these findings indicate that the expression of ezrin Nter acts in a dominant-negative way on HS2 as well as HS1 cells, suggesting that endogenous ezrin participitates in controlling growth and survival of proerythroblasts.
Tyrosine phosphorylation of ezrin depends on the tyrosine kinase activity of oncogenic Kit mutants in HS2 leukemic cells
Ezrin is known to be a substrate for tyrosine kinases. We recently showed that mutations in the kit gene occurred in 86% of HS2 tumors. These mutations target either amino acid residue 814 (D814Y) or 818 (D818Y) causing the autophosphorylation of the SCF receptor and consequently the activation of downstream MAP kinase and PI3 kinase pathways 6 .
As shown in Figure 1 , ezrin was found overexpressed in HS2 cells harboring Kit mutations, but not in the 622 HS2 cells that were autocrine for Epo and not mutated for Kit 6 .
This prompted us to investigate whether Kit mutants were involved in the phosphorylation of ezrin. At first, the tyrosine phosphorylation status of ezrin was investigated in 2 HS2 leukemic cell lines, one harboring the Kit mutation D814Y (606HS2 cells) and one harboring the D818Y mutation (931HS2 cells). Ezrin was immunoprecipitated and analyzed by Western blotting using anti-phosphotyrosine antibodies. Tyrosine phosphorylation of ezrin was detected in both cell lines, treated with pervanadate (Fig.3A) . were assessed by immunoblotting using an anti-phosphotyrosine, an anti-Kit and an anti-VSVG antibody, successively. Then, the expression of transfected proteins was controlled by immunoblotting of whole cell extracts (WCE) with anti-Kit and anti-VSVG antibodies. As shown in Figure 3B , a 140kDa tyrosine-phosphorylated protein corresponding to Kit was coimmunoprecipitated with tyrosine-phosphorylated VSVG-ezrin in Kit-transfected cells. This phosphorylation of ezrin was dependent on Kit kinase activities because a treatment of COS-7 cells co-expressing ezrin and Kit D814Y by PP1 or PP2 abolished the tyrosine phosphorylation of ezrin (Fig.3C) , whereas an IM treatment did not.
Altogether, these data argue for ezrin as a direct substrat of Kit tyrosine kinase activity in vivo.
To test whether ezrin phosphorylation was limited to the Kit mutants, two constitutively activated tyrosine kinases were assayed: the mutated Flt3 receptor (Flt3 D835Y ) frequently identified in human acute myeloid leukemias (AML) 32 and the TEL-Jak2 fusion protein expressed in chronic myeloproliferative disease 33 or acute lymphoblastic leukaemias 34 . The expression vectors were transfected into COS-7 cells along with the VSVG-ezrin expression vector and the expression of transfected proteins was controlled by immunoblotting of WCE with appropriate antibodies (Fig.3D ). The immunoprecipitated ezrin was tyrosinephosphorylated when expressed with Flt3 D835Y but not with TEL-Jak2 ( Fig. 3D top subpanel) .
Altogether, the data indicate that ezrin is phosphorylated on tyrosine by either Kit D814Y or Flt3 D835Y , these proteins being constitutively activated mutants of the class III tyrosine kinase receptor family.
Finally, we determined that ezrin could also be a target for the wild-type Kit stimulated by its ), the expression level of ezrin was less than 3-fold over the control (Fig. 4A ).
The growth kinetics of 606HS2-Ez Y145F and 606HS2-Ez Y353F cells were compared to those of 606HS2-Ez WT and 606HS2-neo cells. A significant reduction in cell proliferation was seen at 48 and 72 hours (Fig.4B) . Then, cell viability was analyzed by trypan blue exclusion ( For
13
606HS2-neo control cells (Fig. 4E) We previously showed the importance of PI3K/Akt and Erk1/Erk2 signaling pathways in the proliferation and survival of HS2 cells 29 . We thus evaluated whether the expression of ezrin Y145F would influence the phosphorylation of Akt and Erk1/Erk2. As shown by FACS analysis (Fig.5B) , the expression of Ezrin Y145F did not change the levels of Akt phosphorylation agreeing with the absence of apoptotic cells in Figure 4 . The levels of phosphorylated Erk1/Erk2 were compared in total extracts from 606HS2-Ez
Y145F
, 606HS2-Ez WT and 606HS2-neo cells by Western blotting using appropriate antibodies. Figure 5C shows that Erk1/2 phosphorylation was strongly reduced in 606HS2-Ez 
Discussion
The erythroleukemia that develops in spi-1 transgenic mice evolves as a multi step process.
The early step is characterized by an accumulation of erythroblasts arrested at a proerythroblastic stage that remain strictly dependent from Epo for survival and proliferation.
These preleukemic cells (HS1) result from the ectopic overexpression of the transcription factor Spi-1/PU.1 in the proerythroblast. Later on, leukemic proerythroblasts (HS2 cells) characterized by autonomous growth and tumorigenicity emerge as a consequence of acquired somatic mutations in the tyrosine kinase receptor Kit. In the present work, we show that ezrin expression is enhanced in leukemic HS2 proerythroblasts compared to preleukemic HS1 cells and we provide evidence that the oncogenic forms of Kit are responsible for ezrin only.
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Functions of ezrin are well-defined in epithelial cells. Ezrin is a membrane cytoskeletal crosslinker that participates in several growth factor receptors signaling leading to cell survival, differentiation, motility, invasion and cell adhesion. However, the role played by ezrin during normal erythroid differentiation remains poorly documented. No abnormality during erythroid development has been reported in ezrin knockout (vil2 null) mice which die with an intestinal epithelium disorganisation 35 . Nevertheless, the protein is detected in the marginal band of chicken erythrocytes suggesting a role in the cytoskeletal organisation 36 .
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HS1 and HS2 cells (our unpublished data from Northern Blot and RQ-PCR analysis).
Moreover, nucleotidic sequencing did not reveal modifications in the primary structure of ezrin in HS2 cells excluding that mutations induce changes in the protein stability. The mechanism(s) by which ezrin become up-regulated during leukemogenesis remains unknown.
Strikingly, an ectopic overexpression of ezrin in preleukemic proerythroblasts is not sufficient to change the behavior of the cells, in terms of Epo dependency for growth and survival.
Altogether, these observations were consistent with the idea that the contribution of ezrin overexpression to oncogenesis required additional stimuli specific of leukemic cells.
Besides the observation that ezrin was overexpressed in HS2 leukemic proerythroblasts, we found that ezrin was tyrosine-phosphorylated. Activating mutations in the SCF receptor Kit is a hallmark of HS2 cells 6 . Because ezrin overexpression was associated to Kit mutation in HS2 cells (Fig.1A) , mutant Kit appeared as a potential player for the tyrosine phosphorylation of ezrin. As a first corroboration, we observed that the tyrosine phosphorylation of ezrin was abolished during treatments of HS2 cells by drugs (PP1 and IM) known to abolish the kinase activities of Kit 6 . Consistent with a functional interaction, ezrin and Kit mutants were coimmunoprecipitated in extracts prepared from COS-7 cells co-transfected with both constructs and the phosphorylation of ezrin was sensitive to inhibitors of the kinase activity of Kit, confirming that the Kit kinase activity was important for the tyrosine phosphorylation of ezrin.
In epithelial cells, ezrin is phosphorylated by some tyrosine kinases. Specifically, the This study is the first that emphasizes a role for oncogenic kinases in the phosphorylation of ezrin in tumors. How might ezrin phosphorylation contribute to erythroleukemia associated to Kit mutations ? Given the increasing evidences that ezrin is a signal transducer in functions as diverse as cell morphogenesis, adhesion, motility, proliferation and survival depending on the cell stimuli and cell type 9, 37 , it is likely that ezrin also behaves as a signal transducer in leukemic cells. The persistent signaling mediated by Kit mutants could block ezrin in a only.
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Phosphorylation on Y145 depends on the conformational activation of ezrin through binding to polyphosphoinositodes and threonine phosphorylation downstream of the Rho or PKC signaling pathways 10, 38 . Although threonine 567 is phosphorylated in HS2 cells (data not shown), the mechanism of its phosphorylation is unknown. We previously showed that the constitutive activation of MAPKs Erk1/2 in HS2 cells is determined by a PKC-dependent mechanism 29 . It is tempting to speculate that PKC participates in the process of ezrin activation during the signaling cascade initiated from Kit mutants and leading to Erk1/2 phosphorylation.
Besides ezrin phosphorylation by Kit, we found that the oncogenic form of Flt3 receptor (Flt3 D835Y ) can also induce the phosphorylation of ezrin on tyrosine. Given that ezrin is also phosphorylated downstream to the PDGF receptor 14 , it is possible to postulate that ezrin is a substrat for the classIII tyrosine kinase receptors, two of them Kit and Flt3 playing a crucial role in hematopoiesis 39 . In this regard, the role of phosphorylated ezrin in proliferation and survival might be seen as a general process when tyrosine kinases are activated in cancer Immunoprecipitates were analyzed by Western blot using anti-phosphotyrosine antibodies For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From
